Phase I Study of HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma (HEROS 3.0)
Latest Information Update: 31 Jan 2024
At a glance
- Drugs CAR-T cell therapies (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Sarcoma
- Focus Adverse reactions
- Acronyms HEROS 3.0
- 23 Jan 2024 Planned End Date changed from 1 Feb 2040 to 31 Dec 2040.
- 23 Jan 2024 Planned primary completion date changed from 1 Feb 2025 to 31 Dec 2027.
- 08 Dec 2021 Status changed from not yet recruiting to recruiting.